A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report
Open Access
- 22 August 2018
- journal article
- case report
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 842
Abstract
High-grade spindle cell sarcomas are a subtype of rare, undifferentiated pleomorphic sarcomas (UPSs) for which diagnosis is difficult and no specific treatment strategies have been established. The limited published data on UPSs suggest an aggressive clinical course, high rates of local recurrence and distant metastasis, and poor prognosis. Here we present the unusual case of a 45-year-old male patient with a lumbosacral UPS extending into the sacrum. An initial diagnosis of a low-grade malignant spindle cell tumor was based on a tumor core biopsy. After complete extensive resection, the diagnosis of an UPS of the lumbosacral region was confirmed by excluding other types of cancers. Despite treatment with neoadjuvant radiotherapy, extensive resection, and adjuvant chemotherapy, the patient presented with multiple pulmonary metastases 3 months after surgery. The patient then began treatment with crizotinib at an oral dose of 450 mg per day, based on the detection of a LMNA-NTRK1 fusion gene in the tumor by next-generation sequencing. Over 18 months of follow-up through July 2018, the patient maintained a near-complete clinical response to crizotinib. The LMNA-NTRK1 fusion was likely the molecular driver of tumorigenesis and metastasis in this patient, and the observed effectiveness of crizotinib treatment provides clinical validation of this molecular target. Molecular and cytogenetic evaluations are critical to accurate prognosis and treatment planning in cases of UPS, especially when treatment options are limited or otherwise exhausted. Molecularly targeted therapy of these rare but aggressive lesions represents a novel treatment option that may lead to fewer toxic side effects and better clinical outcomes.Keywords
This publication has 17 references indexed in Scilit:
- High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methodsJournal of Experimental & Clinical Cancer Research, 2017
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialThe Lancet Oncology, 2017
- Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational studyBMC Medicine, 2017
- Prolactin-producing pituitary adenoma with atypical spindle cell morphology: a case reportWorld Journal of Surgical Oncology, 2015
- Malignant fibrous histiocytoma of the skull base: A neurosurgical nuanceAsian Journal of Neurosurgery, 2015
- Lessons Learned From the Study of 10,000 Patients With Soft Tissue SarcomaAnnals of Surgery, 2014
- An approach to pleomorphic sarcomas: can we subclassify, and does it matter?Laboratory Investigation, 2014
- Undifferentiated high-grade pleomorphic sarcoma (UHPS): Diagnostic criteria, differential diagnosis, and treatment. An attempt to erasure the misnomer "MFH"European Surgery, 2009
- Tracing the Evolution and Function of the Trk Superfamily of Receptor Tyrosine KinasesBrain, Behavior and Evolution, 2006
- Trk receptor tyrosine kinases: A bridge between cancer and neural developmentCancer Letters, 2001